An announcement from Prescient Therapeutics Limited ( (AU:PTX) ) is now available.
Prescient Therapeutics Limited announced an upcoming investor briefing to discuss the next phase towards the approval and commercialization of PTX-100, a promising cancer therapy. The company is advancing its clinical trials, with a Phase 2 study in Cutaneous T cell lymphoma planned for April 2025, highlighting its commitment to innovative cancer treatments and potential market impact.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited is a clinical stage oncology company focused on developing personalized medicine approaches for cancer treatment. The company specializes in targeted and cellular therapies, including PTX-100, a unique GGT-1 inhibitor, and various cell therapy platforms like CellPryme-M, CellPryme-A, and OmniCAR.
YTD Price Performance: -4.00%
Average Trading Volume: 448,975
Technical Sentiment Signal: Buy
Current Market Cap: A$38.66M
For a thorough assessment of PTX stock, go to TipRanks’ Stock Analysis page.